ZA893735B - Method for inhibiting loss of cognitive functions employing a calcium channel blocker alone or in combination with an ace inhibitor - Google Patents

Method for inhibiting loss of cognitive functions employing a calcium channel blocker alone or in combination with an ace inhibitor

Info

Publication number
ZA893735B
ZA893735B ZA893735A ZA893735A ZA893735B ZA 893735 B ZA893735 B ZA 893735B ZA 893735 A ZA893735 A ZA 893735A ZA 893735 A ZA893735 A ZA 893735A ZA 893735 B ZA893735 B ZA 893735B
Authority
ZA
South Africa
Prior art keywords
combination
calcium channel
channel blocker
ace inhibitor
cognitive functions
Prior art date
Application number
ZA893735A
Other languages
English (en)
Inventor
Zola Phillip Horovitz
Phillip Horovitz Zola
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of ZA893735B publication Critical patent/ZA893735B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA893735A 1988-06-01 1989-05-18 Method for inhibiting loss of cognitive functions employing a calcium channel blocker alone or in combination with an ace inhibitor ZA893735B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20317388A 1988-06-01 1988-06-01

Publications (1)

Publication Number Publication Date
ZA893735B true ZA893735B (en) 1990-02-28

Family

ID=22752815

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA893735A ZA893735B (en) 1988-06-01 1989-05-18 Method for inhibiting loss of cognitive functions employing a calcium channel blocker alone or in combination with an ace inhibitor

Country Status (8)

Country Link
EP (1) EP0344995A3 (da)
JP (1) JPH0225422A (da)
KR (1) KR900000082A (da)
AU (1) AU607612B2 (da)
DK (1) DK265789A (da)
HU (1) HUT58521A (da)
IL (1) IL90189A0 (da)
ZA (1) ZA893735B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
US5976816A (en) * 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US6300085B1 (en) 1993-05-03 2001-10-09 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic method for Alzheimer's disease
ATE341342T1 (de) * 2000-01-26 2006-10-15 Astellas Pharma Inc Ace inhibitor-vasopressin antagonist kombinationen
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
JPWO2005011736A1 (ja) * 2003-07-30 2006-09-14 株式会社 東北テクノアーチ アルツハイマー病の予防および／または治療剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105776A (en) * 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4168267A (en) * 1978-10-23 1979-09-18 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl prolines
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4432971A (en) * 1981-08-03 1984-02-21 E. R. Squibb & Sons, Inc. Phosphonamidate compounds
US4452790A (en) * 1982-06-23 1984-06-05 E. R. Squibb & Sons, Inc. Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4504476A (en) * 1983-09-16 1985-03-12 Arnold Schwartz Method of administering calcium channel blocking agents
US4748239A (en) * 1985-06-12 1988-05-31 E. R. Squibb & Sons, Inc. Benzazepine derivatives
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
CA1321753C (en) * 1987-04-27 1993-08-31 Abraham Sudilovsky Method for inhibiting loss of cognitive functions employing an ace inhibitor
US4871731A (en) * 1987-10-07 1989-10-03 Marion Laboratories, Inc. Captopril and diltiazem composition and the like

Also Published As

Publication number Publication date
JPH0225422A (ja) 1990-01-26
EP0344995A2 (en) 1989-12-06
HUT58521A (en) 1992-03-30
EP0344995A3 (en) 1990-12-05
KR900000082A (ko) 1990-01-30
AU607612B2 (en) 1991-03-07
AU3493089A (en) 1989-12-07
IL90189A0 (en) 1989-12-15
DK265789A (da) 1989-12-02
DK265789D0 (da) 1989-05-31

Similar Documents

Publication Publication Date Title
GB8917689D0 (en) Steel laminate gasket
EP0744916A4 (en) SYSTEM WITH A BLOOD-STOPING INSERT
GB9000169D0 (en) Closure with insert for enhanced sealing
EP0426066A3 (en) Ace inhibitors for use for preventing onset of type ii diabetes
HU9400932D0 (en) Linear adhesion inhibitors
ZA882917B (en) Method for inhibiting loss of cognitive functions employing an ace inhibitor
ZA893735B (en) Method for inhibiting loss of cognitive functions employing a calcium channel blocker alone or in combination with an ace inhibitor
AU5494890A (en) Method for preventing or treating anxiety employing a calcium channel blocker
GB2284054B (en) Method for range determination
AU2640488A (en) Method for preventing or treating anxiety employing an ace inhibitor
ZA899924B (en) Renin inhibitors
EP0713496A4 (en) THROMBINE INHIBITORS TARGETED ON FIBRIN
GB9214720D0 (en) Enzyme inhibitors
IE891608L (en) Method for inhibiting loss of cognitive functions employing¹a calcium channel blocker alone or in combination with an¹ace inhibitor
GB9227155D0 (en) Inhibiting calcium carbonate crystal growth
EP0411395A3 (en) Use of ace inhibitors for atherosclerosis-prophylaxis
GB8905114D0 (en) Fading inhibitor for color former
AU110361S (en) Tapping band with seal
GB9311043D0 (en) Inhibitors of nef-cd4 binding
EP0427939A3 (en) Renin inhibitors
AU2840184A (en) Dipeptide ace inhibitors
ZA924089B (en) Novel thrombin inhibitors
HU9502451D0 (en) Combinations of retroviral inhibitors
GB9208596D0 (en) Inhibitors of thrombin
GB9304321D0 (en) Automatic activator